Clinical Trial Update: FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes [Phase 2]

View source ↗

Summary

Phase 2 FRANCIS-ACS trial evaluating A 002 for safety and efficacy in acute coronary syndromes has completed. The sponsor is Anthera Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• A-002

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED